IRA, medication affordability and access, general diabetes prevention, obesity, impacts of drug shortages, drug supply chain
2026 · 1st Quarter (Jan 1 - Mar 31)
NOVO NORDISK INC.
Filed by TARPLIN, DOWNS & YOUNG, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- TARPLIN, DOWNS & YOUNG, LLC
- Client
- NOVO NORDISK INC.
- Filing UUID
- 08671b65-c13b-4284-abb8-0400467f6eb4
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Treat and Reduce Obesity Act, obesity treatment
Federal budget issues
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.